Ironwood Pharmaceuticals (IRWD) Asset Writedowns and Impairment (2014 - 2018)

Ironwood Pharmaceuticals (IRWD) has 4 years of Asset Writedowns and Impairment data on file, last reported at $2.5 million in Q3 2018.

• For the quarter ending Q3 2018, Asset Writedowns and Impairment changed N/A year-over-year to $2.5 million; the trailing twelve-month figure through Sep 2019 stood at $4.3 million (changed 0.0% YoY), and the FY2018 full-year result was $151.8 million, changed N/A from the prior year.
• Asset Writedowns and Impairment grew to $2.5 million in Q3 2018, from $1.8 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $11.4 million in Q4 2014 to a low of $1.8 million in Q2 2018.
• A 4-year average of $6.6 million and a median of $7.0 million in 2014 frame the typical range for Asset Writedowns and Impairment.
• Peak annual rise in Asset Writedowns and Impairment reached 43.82% in 2015, while the deepest fall reached 43.82% in 2015.
• Tracing IRWD's Asset Writedowns and Impairment over 4 years: stood at $11.4 million in 2014, then slumped by 56.14% to $5.0 million in 2015, then soared by 102.0% to $10.1 million in 2016, then plunged by 75.25% to $2.5 million in 2018.
• Business Quant data shows IRWD's Asset Writedowns and Impairment at $2.5 million in Q3 2018, $1.8 million in Q2 2018, and $10.1 million in Q4 2016.